(Boursier.com) — Mauna Kea lost 3.8% to 0.65 euro the day after the announcement of a new clinical study which aims to assess the improvement in diagnostic yield with Cellvizio in the exploration of pulmonary nodules. This study is sponsored by Mayo Clinic and financially supported by Mauna Kea Technologies.
Portzamparc perceives the launch of this study in a very positive way because on the one hand it will allow the company to expand Cellvizio’s proof of concept applied to interventional bronchoscopy and on the other hand it shows that Cellvizio can be combined with multiple platforms. Indeed, the broker points out that the Ion from Intuitive Surgical is the direct competitor of the Monarch from J&J.
©2023 Boursier.com